Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.

Madrigal Pharmaceuticals reported Q3 2026 revenue of $431.27M, up 50.1% YoY, and net income of $55.44M, reversing a prior-year loss. EPS was $1.83 vs. a loss of $4.01. Rezdiffra revenue grew 74% over nine months, with U.S. demand driving quarterly gains. The company expanded its field force and launched Rezdiffra in Germany.

Madrigal Pharmaceuticals stock surged 14.1% to $491.90 after Q3 2026 results beat expectations, with adjusted earnings of $1.83 per share and revenue of $431.3 million. Rezdiffra, the company's flagship drug, drove revenue growth and achieved blockbuster status. CEO Bill Sibold highlighted continued demand and market growth. The company also announced a new clinical trial. Analysts had a positive outlook before the report.

Madrigal Pharmaceuticals (MDGL) reported Q3 EPS of $1.83, beating estimates by $2.66, with revenue of $431.3M, exceeding expectations of $405.27M. The stock closed at $431.16, down 15.47% over 3 months and 3.03% over 12 months. InvestingPro rates its financial health as 'good performance'.

Madrigal Pharmaceuticals (MDGL) reported Q3 adjusted earnings of $1.83 per share, beating estimates of -$0.83. Revenue reached $431.3M, up 50% YoY. Rezdiffra sales drove growth, with $1.1B in year-to-date sales. Shares rose 10.17% in pre-market trading. The company plans a new Phase 3 trial for MASH cirrhosis.

Madrigal Pharmaceuticals (MDGL) reported Q3 earnings of $55.4M, or $1.83 per share, exceeding analyst expectations of a $1.09 per share loss. Revenue was $431.3M, surpassing the $400M forecast.